EMILY REYNOLDS: Open Payments
NPI 1578827416 · ST PETERSBURG, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$974 in 80 payments from 11 companies in 2025. Trend: 2023 $100 · 2024 $847 · 2025 $974
Food & beverage: $974
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $228 |
| Teva Pharmaceuticals USA, Inc. | 43 | $183 |
| Janssen Pharmaceuticals, Inc | 6 | $126 |
| E.R. Squibb & Sons, L.L.C. | 4 | $79 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| Neurocrine BioSciences, Inc. | 2 | $58 |
| Alkermes, Inc. | 2 | $56 |
| Luye Pharma (USA) Ltd. | 1 | $51 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
Products named: VRAYLAR, AUSTEDO XR, INVEGA, COBENFY, CAPLYTA, TRINTELLIX, INGREZZA, ERZOFRI EXTENDED-RELEASE.
Industry payments across FL — which companies pay providers there.
